Boehringer Ingelheim RCV GmbH & Co. KG , Doktor-Boehringer-Gasse 5-11 , 1120 Vienna , Austria.
Department of Chemistry , Vanderbilt University , Nashville , Tennessee 37232-0146 , United States.
J Med Chem. 2018 Oct 11;61(19):8875-8894. doi: 10.1021/acs.jmedchem.8b01108. Epub 2018 Sep 28.
Son of sevenless homologue 1 (SOS1) is a guanine nucleotide exchange factor that catalyzes the exchange of GDP for GTP on RAS. In its active form, GTP-bound RAS is responsible for numerous critical cellular processes. Aberrant RAS activity is involved in ∼30% of all human cancers; hence, SOS1 is an attractive therapeutic target for its role in modulating RAS activation. Here, we describe a new series of benzimidazole-derived SOS1 agonists. Using structure-guided design, we discovered small molecules that increase nucleotide exchange on RAS in vitro at submicromolar concentrations, bind to SOS1 with low double-digit nanomolar affinity, rapidly enhance cellular RAS-GTP levels, and invoke biphasic signaling changes in phosphorylation of ERK 1/2. These compounds represent the most potent series of SOS1 agonists reported to date.
七倍体缺失同源物 1(SOS1)是一种鸟嘌呤核苷酸交换因子,能够催化 RAS 上 GDP 与 GTP 的交换。在其活性形式中,GTP 结合的 RAS 负责许多关键的细胞过程。异常的 RAS 活性参与了所有人类癌症的约 30%;因此,SOS1 作为调节 RAS 激活的作用靶点具有吸引力。在这里,我们描述了一系列新的苯并咪唑衍生的 SOS1 激动剂。通过结构导向设计,我们发现了能够在亚微摩尔浓度下在体外增加 RAS 核苷酸交换的小分子,与 SOS1 的结合亲和力低至双位数纳摩尔,可快速增强细胞内 RAS-GTP 水平,并引发 ERK 1/2 磷酸化的双相信号变化。这些化合物代表了迄今为止报道的最有效的 SOS1 激动剂系列。